Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
5 pending office actions • 3 art units • 3 examiners • 0 of 5 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Osiris Therapeutics Inc. maintains a robust prosecution pipeline within the Biotechnology & Pharmaceuticals technology area, currently managing 5 pending office actions. This level of activity indicates a significant and ongoing investment in protecting its intellectual property. These actions are distributed across 3 distinct examiners, providing a variety of perspectives on the company's patent applications and reducing the impact of any single examiner's review style.
The portfolio's reach extends across 3 distinct art units, suggesting a diverse range of technical focuses within the biotech and pharmaceutical fields. VAN BUREN, LAUREN K is the busiest examiner for the company, handling 3 pending office actions. This means that while there are 3 distinct examiners involved, a majority of the 5 pending actions are concentrated under a single individual's review. This concentration with a single examiner across multiple art units could lead to more consistent outcomes for the majority of the company's pending matters.
Based on the USPTO statutory response window for each pending office action. 3 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 3 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 only | 1 (20%) |
| §103 only | 2 (40%) |
| Double-patenting only | 2 (40%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| VAN BUREN, LAUREN K | 3 | 39.8% | +58.1% |
| TRUONG, QUANGLONG N | 1 | 78.8% | +23.6% |
| GHALI, ISIS A D | 1 | 27.9% | +41.6% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17854688 | DISRUPTED CARTILAGE PRODUCTS | GHALI, ISIS A D | 93d overdue |
| 18696785 | COMPOSITIONS OF DECIDUA TISSUE AND USES THEREOF | TRUONG, QUANGLONG N | 3d overdue |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 5 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17854688 | DISRUPTED CARTILAGE PRODUCTS | GHALI, ISIS A D | 93d overdue |
| 18696785 | COMPOSITIONS OF DECIDUA TISSUE AND USES THEREOF | TRUONG, QUANGLONG N | 3d overdue |
| 18584293 | IMMUNOCOMPATIBLE AMNIOTIC MEMBRANE PRODUCTS | VAN BUREN, LAUREN K | 34d |
| 18632923 | THERAPEUTIC PRODUCTS COMPRISING VITALIZED PLACENTAL DISPERSIONS | VAN BUREN, LAUREN K | — |
| 17401758 | IMMUNOCOMPATIBLE AMNIOTIC MEMBRANE PRODUCTS | VAN BUREN, LAUREN K | — |
| Art Unit | Apps |
|---|---|
| 1638 | 3 |
| 1615 | 1 |
| 1611 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18632923 | THERAPEUTIC PRODUCTS COMPRISING VITALIZED PLACENTAL DISPERSIONS | VAN BUREN, LAUREN K | 1638 | DP | Non-Final OA | — | Pending | Apr 11, 2024 |
| 18696785 | COMPOSITIONS OF DECIDUA TISSUE AND USES THEREOF | TRUONG, QUANGLONG N | 1615 | §101 | Final Rejection | 3d overdue | Pending | Mar 28, 2024 |
| 18584293 | IMMUNOCOMPATIBLE AMNIOTIC MEMBRANE PRODUCTS | VAN BUREN, LAUREN K | 1638 | DP | Final Rejection | 34d | Pending | Feb 22, 2024 |
| 17854688 | DISRUPTED CARTILAGE PRODUCTS | GHALI, ISIS A D | 1611 | §103Other | Final Rejection | 93d overdue | Pending | Jun 30, 2022 |
| 17401758 | IMMUNOCOMPATIBLE AMNIOTIC MEMBRANE PRODUCTS | VAN BUREN, LAUREN K | 1638 | §103 | Non-Final OA | — | Pending | Aug 13, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial